Tirzepatide, characterized by its dual agonist properties, has already gained FDA approval and demonstrated impressive efficacy
40BleiAT, OlafssonS, WebsterS, LevyR
Important safety considerations include a boxed warning for medullary thyroid carcinoma risk (contraindicated in patients with personal/family history of MTC or Multiple Endocrine Neoplasia syndrome type 2), and warnings regarding pancreatitis, gallbladder disease, and hypoglycemia risk when used with insulin or sulfonylureas
But the body composition changes, the shift from losing general weight to specifically losing fat while preserving lean tissue, become more apparent over months of consistent use
Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis
: :